Mishu L, Callahan G, Allebban Z, Maddux J M, Boone T C, Souza L M, Lothrop C D
Department of Environmental Practice, College of Veterinary Medicine, University of Tennessee, Knoxville 37901-1071.
J Am Vet Med Assoc. 1992 Jun 15;200(12):1957-64.
Recombinant canine granulocyte colony-stimulating factor (rcG-CSF) was administered to clinically normal dogs, cyclic-hematopoietic dogs, and dogs undergoing autologous bone marrow transplantation, to determine whether rcG-CSF could be used to stimulate WBC production and function in normal and neutropenic dogs. To the normal dogs, rcG-CSF was administered by SC injection at rates of 1 microgram/kg of body weight, q 12 h; 2 micrograms/kg, q 12 h; or 5 micrograms/kg, q 12 h. A significant dose-dependent increase in the WBC count resulted from the stimulation of bone marrow progenitor cells. The increased WBC count was characterized by mature neutrophilia and monocytosis. Neutrophil myeloperoxidase and phagocytic activity were normal in rcG-CSF-treated normal dogs, demonstrating the production of normal functional neutrophils in response to rcG-CSF treatment. Recombinant canine G-CSF prevented neutropenia and associated clinical signs but did not completely eliminate the cycling of neutrophils in cyclic-hematopoietic dogs when it was administered at rates of 1 microgram/kg, q 12 h, and 2.5 micrograms/kg, q 12 h. The time to bone marrow reconstitution was not decreased in dogs treated with rcG-CSF at a rate of 2.5 micrograms/kg, q 12 h, for 13 days following autologous bone marrow transplantation. On the basis of our findings, we suggest that treatment with rcG-CSF is an effective way to stimulate myelopoiesis in dogs, but that the dose of rcG-CSF required to stimulate WBC production will vary depending on the cause of neutropenia. Recombinant canine G-CSF should be useful in stimulating production and maintaining function of WBC for treatment of clinical diseases seen commonly in veterinary practice.
将重组犬粒细胞集落刺激因子（rcG-CSF）给予临床正常犬、周期性造血犬以及接受自体骨髓移植的犬，以确定rcG-CSF是否可用于刺激正常犬和中性粒细胞减少犬的白细胞生成及功能。对于正常犬，rcG-CSF通过皮下注射给药，剂量分别为1微克/千克体重，每12小时一次；2微克/千克，每12小时一次；或5微克/千克，每12小时一次。骨髓祖细胞受到刺激后，白细胞计数出现显著的剂量依赖性增加。白细胞计数增加的特征为成熟中性粒细胞增多和单核细胞增多。在接受rcG-CSF治疗的正常犬中，中性粒细胞髓过氧化物酶和吞噬活性正常，表明对rcG-CSF治疗有正常功能的中性粒细胞生成。当以1微克/千克，每12小时一次和2.5微克/千克，每12小时一次的剂量给药时，重组犬G-CSF可预防中性粒细胞减少及相关临床症状，但并未完全消除周期性造血犬中性粒细胞的循环。自体骨髓移植后，以2.5微克/千克，每12小时一次的剂量给予rcG-CSF治疗13天的犬，骨髓重建时间并未缩短。根据我们的研究结果，我们认为用rcG-CSF治疗是刺激犬骨髓生成的有效方法，但刺激白细胞生成所需的rcG-CSF剂量将因中性粒细胞减少的原因而异。重组犬G-CSF在刺激白细胞生成和维持其功能以治疗兽医临床常见疾病方面应具有应用价值。
